engleski

Successful use of activated recombinant factor VII in life threatening bleeding after thoracic surgery

Our modest experience with the clinical use of rFVIIa suggests that this agent may provide effective, maintained hemostasis following life-threatening postoperative bleeding in thoracic surgery. We believe that the agent contributed considerably to the maintenance of satisfactory clinical and laboratory status in our patients. Despite these favorable results, hzowever, further research is clearly needed to identify optimal treatment strategy, patient selection, and safety of treatment in this indication.

rFVII; bleeding; thoracic surgery; complications

nije evidentirano